Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab plus pembrolizumab and chemotherapy for first-line CLDN18.2-positive, PD-L1-positive HER2-negative gastric or gastroesophageal junction adenocarcinoma
2024-519773-19-00Phase 3Authorised
- Sponsor
- Astellas Pharma
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and gastric cancer (GC) comparing Vyloy + Keytruda + chemotherapy with Keytruda + chemotherapy (2 arms). Primary endpoint: Overall survival. Planned start Jul 2025; status: authorised.
02
Drugs
zolbetuximabpembrolizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on 2024-519773-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519773-19-00.